Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 28OTHER 20NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 16Magnetic Resonance Spectroscopy 13Vincristine 8Dexamethasone 6Cyclophosphamide 6Radiotherapy 5Radiation 5Leucovorin 5Lenalidomide 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5dexamethasone acetate 4dexamethasone 21-phosphate 4daratumumab 4auricularum 4X-Rays 4Standard of Care 4Radiotherapy, Conformal 4Practice Guidelines as Topic 4Etoposide 4Cytarabine 4Bortezomib 4Biopsy 4pegaspargase 3Taxes 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Prednisone 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Capecitabine × 30 days × Clear all
NCT02445391 2026-06-01

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
415 enrolled 15 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡